

APPENDIX 1: Author Relationships With Industry and Other Entities (Comprehensive) — 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants

Note: Those **highlighted** indicate relevant RWI

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Gordon F. Tomaselli, Chair	Albert Einstein College of Medicine – The Marilyn & Stanley M. Katz Dean Montefiore Medicine – Executive Vice President and Chief Academic Officer	None	None	None	None	None	None
Kenneth W. Mahaffey, Vice Chair	Stanford Center for Clinical Research—Director; Stanford Department of Medicine—Vice-Chair of Clinical Research, Department of Medicine Stanford Center for Clinical Research	<ul style="list-style-type: none"> • AstraZeneca† • Boehringer Ingelheim Pharmaceutical† • Bristol Myers Squibb† • Janssen Pharmaceuticals • Merck • Myokardia • Novartis • Oculeve • Portola • Radiometer • Springer • Theravance, Inc. • WebMD 	None	None	None	<ul style="list-style-type: none"> • Afferent† • Amgen • AstraZeneca • Ferring Pharmaceuticals • Medtronic • Merck • Sanofi • St Jude • Verily (Google) 	None
Adam Cuker	University of Pennsylvania— Associate Professor of Medicine and of Pathology & Laboratory Medicine	Synergy, CRO†	None	None	None	<ul style="list-style-type: none"> • Alexion • Bayer • Novo Nordisk • Pfizer • Sanofi • Spark 	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
	Harvard Medical School – Instructor						
Roxana Mehran	Icahn School of Medicine at Mount Sinai— Director of Interventional Cardiovascular Research and Clinical Trials and Professor of Medicine (Cardiology) and Population Health Science and Policy	<ul style="list-style-type: none"> • Abbot Laboratories† • Boston Scientific • Bristol-Myers Squibb† • Idorsia Pharma Ltd* • Janssen Scientific Affairs, LLC • Medscape/WebMD • Regeneron Pharmaceuticals* • Roivant Sciences • Sanofi-Aventis† • Siemens • Spectranetics/Philips /Volcano Corp† • Watermark Research Partners 	None	<ul style="list-style-type: none"> • Claret Medical • Elixir Medical 	<ul style="list-style-type: none"> • CardioVascular Research Foundation* 	<ul style="list-style-type: none"> • Abbott Laboratories† • AstraZeneca Pharmaceuticals LP† • Bayer Healthcare Pharmaceuticals† • Beth Israel Deaconess Medical Center† • Bristol-Myers Squibb Company • CSL Behring† • Daiichi Sankyo Inc. † • Medtronic Vascular, Inc. • Novartis Pharmaceuticals • OrbusNeich 	<ul style="list-style-type: none"> • Defendant, Referral for LVAD transplantation, 2018* • Defendant, Stenosis underestimation, 2018*
Steven R. Messe	University of Pennsylvania— Associate Professor of Neurology	None	None	None	None	None	None
Alexander Perino	Stanford University Medical Center—Fellow in Cardiac Electrophysiology	None	None	None	None	<ul style="list-style-type: none"> • None 	None
Charles V. Pollack, Jr. ‡	Thomas Jefferson University Hospital—Professor of Emergency Medicine and Associate Provost	<ul style="list-style-type: none"> • AstraZeneca† • Boehringer Ingelheim† • Daiichi-Sankyo • Janssen Pharmaceuticals† • Pfizer† 	None	None	<ul style="list-style-type: none"> • AstraZeneca† • Boehringer Ingelheim† • Daiichi-Sankyo† • Janssen Pharmaceuticals† • Portola† • CSL Behring† 	None	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Fatima Rodriguez	Stanford University Medical Center – Assistant Professor of Medicine	None	None	None	None	None	None
Ravindra Sarode	University of Texas Southwestern— Professor of Pathology, Chief of Pathology and Medical Director of Clinical Laboratory Services, UT Southwestern Medical Center, and Director, Transfusion Medicine and Hemostasis	<ul style="list-style-type: none"> • Ablynx • CSL Behring • Octapharma • Portola 	None	None	None	None	None
Deborah M. Siegal	McMaster University—Clinical Scholar, Division of Hematology and Thromboembolism	<ul style="list-style-type: none"> • Bristol Myers Squibb /Pfizer • Portola 	None	None	None	None	None
Barbara S. Wiggins	Medical University of South Carolina—Clinical Pharmacy Specialist, Cardiology Department of Pharmacy Services	None	None	None	None	None	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥\$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinicaldocuments/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

(s) Significant relationship.

(n) No financial benefit.

‡ Relationship with this company is limited to enrolling patients in clinical trials. This disclosure was entered under the Clinical Trial Enroller category in the ACC’s disclosure system. To appear in this category, the author acknowledges that there is no direct or institutional relationship with the trial sponsor as defined in the ACC/AHA Disclosure Policy for Writing Committees.

ACC=American College of Cardiology; UT=University of Texas.

